|drug4680||pulse oximeter Wiki||1.00|
|drug4023||To assess for development of IgG antibodies against SARS-CoV2 Wiki||1.00|
|D058070||Asymptomatic Diseases NIH||0.58|
|D003333||Coronaviridae Infections NIH||0.45|
|D012327||RNA Virus Infections NIH||0.41|
There is one clinical trial.
The clinical guidance for 90 percent of infected COVID-19 adult patients who do not meet eligibility for inpatient admission is to self-isolate. To support these patients, alternatives to in-person care are needed to manage an unpredictable clinical course; identify and intercept patients rapidly deteriorating at home, prevent viral spread during in-person visits; and minimize future surges in emergency departments (EDs). In addition, fingertip pulse oximeters have been proposed to improve in-home early detection of respiratory deteriorations but are untested and the operational infrastructure to support large-scale monitoring is limited. While telemedicine has been widely adopted during the pandemic as an alternative to conventional outpatient care, limited telemedicine access may be exacerbating observed disparities for Black and Latino patients. In our health system, Black and Latino patients used video-visits 15 percent less often than white patients. Text messaging and phone calls may improve healthcare access for communities of color, but the evidence for these telecommunication modalities to be effective and improve equity are limited. The University of Pennsylvania Health System (UPHS) developed and deployed COVID Watch to improve access to health care for COVID-19 patients who are self-isolating at home. COVID Watch sends twice-daily, scheduled text messages to assess patients for shortness of breath using a clinical algorithm to determine whether patients need an urgent escalation to a team of dedicated, on-call nurses within one hour. These nurses are supported by an on-call team of clinicians who can conduct urgent phone or video assessments. Patients can also trigger the algorithmic assessment independent of the scheduled messages. As of May 21, 2020, COVID Watch has managed 3,628 COVID-19 patients at home, of which 1,295 are confirmed COVID-19 positive; of these, 61 percent are Black or Latino, higher than the proportion of all UPHS COVID-19 positive patients that are Black or Latino (55 percent).
Description: Outcome includes time-based and categorical clinical outcomes. Time-based measures will be assessed at 30 days and begin when a COVID-19 patient was tested (e.g., nasopharyngeal swab) in outpatient and ED settings, or starting at the time of discharge from the hospital if enrolled in COVID Watch as an inpatient. Staying safe and out of the hospital using Days Alive and Out of Hospital (DAOH) since the date of the positive COVID-19 test. Initial analyses will include in-hospital deaths. Deaths that occur outside the hospital in 2020 will be added to a follow up analysis when National Death Index (NDI) becomes available (est. January 2021).Measure: Difference in Days Alive and Out of Hospital Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports